LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.26 -8.43

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.24

Max

3.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M -59M
Darbuotojai	142
EBITDA	-19M -58M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+185.67% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-13

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-185M 921M
Ankstesnė atidarymo kaina	11.69
Ankstesnė uždarymo kaina	3.26

Naujienos nuotaikos

By Acuity

50%

175 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-11 22:15; UTC

Įsigijimai, susijungimai, perėmimai

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026-05-11 23:46; UTC

Rinkos pokalbiai

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026-05-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026-05-11 23:33; UTC

Rinkos pokalbiai

Gold Rises on Possible Position Adjustments -- Market Talk

2026-05-11 22:37; UTC

Rinkos pokalbiai

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026-05-11 22:32; UTC

Uždarbis

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026-05-11 22:02; UTC

Rinkos pokalbiai

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026-05-11 21:49; UTC

Uždarbis

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026-05-11 21:42; UTC

Rinkos pokalbiai

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026-05-11 21:32; UTC

Įsigijimai, susijungimai, perėmimai

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026-05-11 21:31; UTC

Įsigijimai, susijungimai, perėmimai

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026-05-11 21:23; UTC

Įsigijimai, susijungimai, perėmimai

CSG Systems Sale to NEC Gets CFIUS Clearance

2026-05-11 21:12; UTC

Uždarbis

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026-05-11 21:12; UTC

Uždarbis

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026-05-11 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-11 20:44; UTC

Uždarbis

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026-05-11 20:43; UTC

Uždarbis

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026-05-11 20:32; UTC

Uždarbis

CleanSpark 2Q Rev $136.4M >CLSK

2026-05-11 20:30; UTC

Uždarbis

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Cont Ops EPS $2.24 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Rev $1.6B >STE

2026-05-11 20:30; UTC

Uždarbis

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026-05-11 20:30; UTC

Uždarbis

Steris 4Q Adj EPS $2.83 >STE

2026-05-11 20:22; UTC

Karštos akcijos

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026-05-11 19:37; UTC

Uždarbis

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026-05-11 19:32; UTC

Rinkos pokalbiai

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

185.67% į viršų

12 mėnesių prognozė

Vidutinis 10.17 USD 185.67%

Aukščiausias 16 USD

Žemiausias 7 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

175 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.